Business Description
Clover Health Investments Corp
NAICS : 525120
SIC : 6324
ISIN : US18914F1030
Share Class Description:
FRA:7QD: Ordinary Shares - Class ATotal Employee Number:
724Compare
Compare
Traded in other countries / regions
CLOV.USA7QD.GermanyCLOV34.Brazil IPO Date
2021-06-30Description
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.49 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.66 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.7 | |||||
3-Year EBITDA Growth Rate | 32.3 | |||||
3-Year EPS without NRI Growth Rate | 34.3 | |||||
3-Year FCF Growth Rate | 32.5 | |||||
3-Year Book Growth Rate | -7.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 22.95 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.98 | |||||
9-Day RSI | 46.75 | |||||
14-Day RSI | 54.92 | |||||
3-1 Month Momentum % | 96.94 | |||||
6-1 Month Momentum % | 54.88 | |||||
12-1 Month Momentum % | 24.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.33 | |||||
Quick Ratio | 1.33 | |||||
Cash Ratio | 0.6 | |||||
Days Payable | 6.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.8 | |||||
Shareholder Yield % | 1.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 18.39 | |||||
Operating Margin % | -2.57 | |||||
Net Margin % | -2.58 | |||||
EBITDA Margin % | -2.5 | |||||
FCF Margin % | 2.51 | |||||
OCF Margin % | 2.64 | |||||
ROE % | -17.06 | |||||
ROA % | -9.63 | |||||
ROIC % | -23.82 | |||||
3-Year ROIIC % | -658.62 | |||||
ROC (Joel Greenblatt) % | -981.64 | |||||
ROCE % | -15.81 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 375 | |||||
PS Ratio | 1.09 | |||||
PB Ratio | 7.21 | |||||
Price-to-Tangible-Book | 7.33 | |||||
Price-to-Free-Cash-Flow | 46.55 | |||||
Price-to-Operating-Cash-Flow | 43.92 | |||||
EV-to-EBIT | -37.27 | |||||
EV-to-Forward-EBIT | 11.8 | |||||
EV-to-EBITDA | -38.44 | |||||
EV-to-Forward-EBITDA | 360.02 | |||||
EV-to-Revenue | 0.96 | |||||
EV-to-Forward-Revenue | 0.73 | |||||
EV-to-FCF | 38.91 | |||||
Price-to-GF-Value | 1.16 | |||||
| Price-to-Net-Current-Asset-Value | 26.56 | |||||
Earnings Yield (Greenblatt) % | -2.68 | |||||
FCF Yield % | 2.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Clover Health Investments Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,901.793 | ||
| EPS (TTM) (€) | -0.102 | ||
| Beta | 2.06 | ||
| 3-Year Sharpe Ratio | 1.02 | ||
| 3-Year Sortino Ratio | 2.68 | ||
| Volatility % | 90.43 | ||
| 14-Day RSI | 54.92 | ||
| 14-Day ATR (€) | 0.163793 | ||
| 20-Day SMA (€) | 4.3615 | ||
| 12-1 Month Momentum % | 24.81 | ||
| 52-Week Range (€) | 1.41 - 4.92 | ||
| Shares Outstanding (Mil) | 526.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clover Health Investments Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clover Health Investments Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 17:00 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 17:00 | In 28 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 27 days | ||
| General meeting for 2026 | 2026-06-10 11:00 | 3.30 (-0.30%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 17:00 | 2.22 (+0.45%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 2.22 (+0.45%) | ||
| Guidance call for 2026 | 2026-03-10 09:20 | 1.67 (+1.09%) | ||
| Annual report for 2025 | 2026-02-27 | 1.74 (+1.13%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 17:00 | 1.81 (+8.66%) |
Show
Entries
Clover Health Investments Corp Frequently Asked Questions
What is Clover Health Investments Corp(FRA:7QD)'s stock price today?
The current price of FRA:7QD is €4.25. The 52 week high of FRA:7QD is €4.92 and 52 week low is €1.41.
When is next earnings date of Clover Health Investments Corp(FRA:7QD)?
The next earnings date of Clover Health Investments Corp(FRA:7QD) is 2026-08-05 Est..
Does Clover Health Investments Corp(FRA:7QD) pay dividends? If so, how much?
Clover Health Investments Corp(FRA:7QD) does not pay dividend.
Press Release
Articles on Clover Health Investments Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers